Plus Therapeutics, Inc. has announced the initiation of the ReSPECT-LM dose optimization trial for its product REYOBIQ™ (rhenium Re186 obisbemeda) aimed at treating leptomeningeal metastases (LM).
ReSPECT-LM Dose Optimization Trial Design The study design is consistent with the FDA’s Project Optimus, and aims to optimize treatment dosing for maximum efficacy and safety. The primary objectives ...
Plus Therapeutics, Inc. has begun treating patients in its ReSPECT-LM dose optimization trial for REYOBIQ (rhenium Re186 obisbemeda), targeting leptomeningeal metastases (LM), a severe complication of ...
HOUSTON, July 08, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform ...
HOUSTON, June 30, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (PSTV) (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced ...
HOUSTON, July 08, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform ...
ReSPECT-LM Dose Optimization Trial Design The study design is consistent with the FDA's Project Optimus, and aims to optimize treatment dosing for maximum efficacy and safety. The primary objectives ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback